Physician profile
Joann Nguyen
NPI 1205177854
$29,059.88
in general payments reported to CMS, 2019-2025
51 companies · $4,709 in 2025
The $4,709 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,016 · 2020: $2,257 · 2021: $3,993 · 2022: $3,957 · 2023: $5,119 · 2024: $4,008 · 2025: $4,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,818.47 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,910.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $3,239.81 | 2019-2025 | |
| Novo Nordisk INC | $1,945.41 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,623.34 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $1,589.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $1,560.48 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,319.83 | 2019-2025 | |
| Amarin Pharma, INC. | $1,139.14 | 2019-2023 | |
| Amgen INC. | $940.02 | 2019-2025 | Prolia, Evenity, Repatha |
| Aimmune Therapeutics, INC. | $713.15 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $703.13 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Esperion Therapeutics, INC. | $673.15 | 2020-2025 | Nexletol, Nexlizet |
| Nestle Healthcare Nutrition INC. | $661.74 | 2021-2023 | |
| Astellas Pharma US INC | $657.72 | 2020-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $648.19 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.